Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Other Accumulated Expenses (2019 - 2025)

Historic Other Accumulated Expenses for Bioadaptives (BDPT) over the last 6 years, with Q3 2025 value amounting to $1019.0.

  • Bioadaptives' Other Accumulated Expenses changed 0.0% to $1019.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1019.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $150000.0 for FY2024, which is 1462031.4% up from last year.
  • Latest data reveals that Bioadaptives reported Other Accumulated Expenses of $1019.0 as of Q3 2025, which was down 0.0% from $1018.0 recorded in Q2 2025.
  • Over the past 5 years, Bioadaptives' Other Accumulated Expenses peaked at $150000.0 during Q4 2024, and registered a low of $1015.0 during Q4 2022.
  • Moreover, its 4-year median value for Other Accumulated Expenses was $1019.0 (2023), whereas its average is $15916.9.
  • As far as peak fluctuations go, Bioadaptives' Other Accumulated Expenses soared by 1462031.4% in 2024, and later tumbled by 39.14% in 2025.
  • Bioadaptives' Other Accumulated Expenses (Quarter) stood at $1015.0 in 2022, then grew by 0.39% to $1019.0 in 2023, then surged by 14620.31% to $150000.0 in 2024, then tumbled by 99.32% to $1019.0 in 2025.
  • Its last three reported values are $1019.0 in Q3 2025, $1018.0 for Q2 2025, and $1019.0 during Q1 2025.